Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Darolutamide→

Darolutamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1297538-32-9
Molecular formula
C19H19ClN6O2
Molecular weight
398.8 g/mol
Drug class
Non-steroidal androgen receptor inhibitortargeted antineoplastic
Mechanism of action
Binds androgen receptors and inhibits androgen binding, receptor nuclear translocation and androgen-receptor-mediated transcription, suppressing prostate cancer cell growth.
Indications / reported uses
  • Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in combination with androgen deprivation therapy
  • Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy and docetaxel under the applicable US product indication

Sources: US DailyMed — NUBEQA (darolutamide) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Darolutamide Environmental Risk Assessment (ERA) (the Darolutamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.